Ceftazidime–avibactam plus aztreonam for recurrent NDM-Producing Klebsiella pneumoniae infection following polymyxin B exposure in an extremely preterm infant: a case report

Background Therapeutic options for metallo-β-lactamase (MBL)-producing carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in neonates are extremely limited, particularly after the emergence of polymyxin resistance. Evidence supporting ceftazidime-avibactam (CAZ-AVI) plus aztreonam (ATM) in extremely preterm infants remains scarce. Case Presentation A male infant born at 27 +6 weeks’ gestation with a birth weight of 1,200 g developed perforated necrotizing enterocolitis requiring bowel resection and enterostomy. During hospitalization, he experienced three episodes of NDM-producing CRKP bloodstream infection. The polymyxin B MIC increased from 1 μg/mL in the initial isolate to 4 μg/mL in the third isolate, with the latter result confirmed by repeat broth microdilution testing. Severe intestinal failure-associated liver disease (IFALD) also developed, with a peak direct bilirubin concentration of 426 μmol/L. Synergy testing demonstrated restored activity of CAZ-AVI plus ATM despite resistance to each agent alone. The infant received both CAZ-AVI (50 mg/kg every 8 h) and ATM (30 mg/kg every 8 h) for approximately 7 weeks. Management also included high dose pure fish oil-lipid emulsions (FO-ILE) therapy, anticoagulation guided by thrombotic biomarkers, individualized nutritional support, and delayed intestinal reconstruction. Results Blood cultures and mNGS became negative following combination therapy. After restoration of intestinal continuity, inflammatory markers normalized, cholestasis resolved completely, and full enteral autonomy was achieved. No treatment-related adverse events or renal dysfunction occurred. At 15 months of age (12 months corrected age), growth and neurodevelopment were satisfactory. Conclusion Successful treatment required not only synergistic antimicrobial therapy but also early initiation of oral or enteral feeding through intestinal reconstruction and FO-ILE therapy. This case highlights the importance of integrating antimicrobial, surgical, nutritional strategies in extremely preterm infants with multidrug-resistant infections complicated by intestinal failure and IFALD.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-20
DOI
https://doi.org/10.3389/fphar.2026.2006744
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ceftazidime–avibactam plus aztreonam for recurrent NDM-Producing Klebsiella pneumoniae infection following polymyxin B exposure in an extremely preterm infant: a case report

蒋小平, Xue Han, Liang Huang, Wei Zhou et al.
2 links
Frontiers in Pharmacology
Antibiotic Resistance in Bacteria
article

Ceftazidime–avibactam plus aztreonam for recurrent NDM-Producing Klebsiella pneumoniae infection following polymyxin B exposure in an extremely preterm infant: a case report

蒋小平, Xue Han, Liang Huang, Wei Zhou, Min Zhang, Li Zhang
article en

Abstract

Background Therapeutic options for metallo-β-lactamase (MBL)-producing carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in neonates are extremely limited, particularly after the emergence of polymyxin resistance. Evidence supporting ceftazidime-avibactam (CAZ-AVI) plus aztreonam (ATM) in extremely preterm infants remains scarce. Case Presentation A male infant born at 27 +6 weeks’ gestation with a birth weight of 1,200 g developed perforated necrotizing enterocolitis requiring bowel resection and enterostomy. During hospitalization, he experienced three episodes of NDM-producing CRKP bloodstream infection. The polymyxin B MIC increased from 1 μg/mL in the initial isolate to 4 μg/mL in the third isolate, with the latter result confirmed by repeat broth microdilution testing. Severe intestinal failure-associated liver disease (IFALD) also developed, with a peak direct bilirubin concentration of 426 μmol/L. Synergy testing demonstrated restored activity of CAZ-AVI plus ATM despite resistance to each agent alone. The infant received both CAZ-AVI (50 mg/kg every 8 h) and ATM (30 mg/kg every 8 h) for approximately 7 weeks. Management also included high dose pure fish oil-lipid emulsions (FO-ILE) therapy, anticoagulation guided by thrombotic biomarkers, individualized nutritional support, and delayed intestinal reconstruction. Results Blood cultures and mNGS became negative following combination therapy. After restoration of intestinal continuity, inflammatory markers normalized, cholestasis resolved completely, and full enteral autonomy was achieved. No treatment-related adverse events or renal dysfunction occurred. At 15 months of age (12 months corrected age), growth and neurodevelopment were satisfactory. Conclusion Successful treatment required not only synergistic antimicrobial therapy but also early initiation of oral or enteral feeding through intestinal reconstruction and FO-ILE therapy. This case highlights the importance of integrating antimicrobial, surgical, nutritional strategies in extremely preterm infants with multidrug-resistant infections complicated by intestinal failure and IFALD.

Frontiers in PharmacologyVol. 17
Sichuan University (CN), West China Second University Hospital of Sichuan University (CN), West China Hospital of Sichuan University (CN)
Good health and well-being
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon